Also, in a randomized double-blind clinical trial, CANTOS, a significant reduction in the number of adverse cardiovascular diseases was demonstrated under the influence of the specific IL-1β blocker, canakinumab (35). This evidence concerns the gene IL1B and cardiovascular disorder.